Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease

Kyle M. Rose; Heather L. Huelster; Joshua J. Meeks; Bishoy M. Faltas; Guru P. Sonpavde; Seth P. Lerner; Jeffrey S. Ross; Philippe E. Spiess; G. Daniel Grass; Rohit K. Jain; Ashish M. Kamat; Aram Vosoughi; Liang Wang; Xuefeng Wang; Roger Li

doi:10.1038/s41585-023-00725-2

Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease

Kyle M. Rose, Heather L. Huelster, Joshua J. Meeks, Bishoy M. Faltas, Guru P. Sonpavde, Seth P. Lerner, Jeffrey S. Ross, Philippe E. Spiess, G. Daniel Grass, Rohit K. Jain, Ashish M. Kamat, Aram Vosoughi, Liang Wang, Xuefeng Wang, Roger Li

Urology

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Precision medicine has transformed the way urothelial carcinoma is managed. However, current practices are limited by the availability of tissue samples for genomic profiling and the spatial and temporal molecular heterogeneity observed in many studies. Among rapidly advancing genomic sequencing technologies, non-invasive liquid biopsy has emerged as a promising diagnostic tool to reproduce tumour genomics, and has shown potential to be integrated in several aspects of clinical care. In urothelial carcinoma, liquid biopsies such as plasma circulating tumour DNA (ctDNA) and urinary tumour DNA (utDNA) have been investigated as a surrogates for tumour biopsies and might bridge many shortfalls currently faced by clinicians. Both ctDNA and utDNA seem really promising in urothelial carcinoma diagnosis, staging and prognosis, response to therapy monitoring, detection of minimal residual disease and surveillance. The use of liquid biopsies in patients with urothelial carcinoma could further advance precision medicine in this population, facilitating personalized patient monitoring through non-invasive assays.

Original language	English (US)
Pages (from-to)	406-419
Number of pages	14
Journal	Nature Reviews Urology
Volume	20
Issue number	7
DOIs	https://doi.org/10.1038/s41585-023-00725-2
State	Published - Jul 2023

ASJC Scopus subject areas

Urology

Access to Document

10.1038/s41585-023-00725-2

Cite this

Rose, K. M., Huelster, H. L., Meeks, J. J., Faltas, B. M., Sonpavde, G. P., Lerner, S. P., Ross, J. S., Spiess, P. E., Grass, G. D., Jain, R. K., Kamat, A. M., Vosoughi, A., Wang, L., Wang, X., & Li, R. (2023). Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease. Nature Reviews Urology, 20(7), 406-419. https://doi.org/10.1038/s41585-023-00725-2

Rose, KM, Huelster, HL, Meeks, JJ, Faltas, BM, Sonpavde, GP, Lerner, SP, Ross, JS, Spiess, PE, Grass, GD, Jain, RK, Kamat, AM, Vosoughi, A, Wang, L, Wang, X & Li, R 2023, 'Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease', Nature Reviews Urology, vol. 20, no. 7, pp. 406-419. https://doi.org/10.1038/s41585-023-00725-2

@article{19d0bbb2d546410d98724350f1d797a3,

title = "Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease",

abstract = "Precision medicine has transformed the way urothelial carcinoma is managed. However, current practices are limited by the availability of tissue samples for genomic profiling and the spatial and temporal molecular heterogeneity observed in many studies. Among rapidly advancing genomic sequencing technologies, non-invasive liquid biopsy has emerged as a promising diagnostic tool to reproduce tumour genomics, and has shown potential to be integrated in several aspects of clinical care. In urothelial carcinoma, liquid biopsies such as plasma circulating tumour DNA (ctDNA) and urinary tumour DNA (utDNA) have been investigated as a surrogates for tumour biopsies and might bridge many shortfalls currently faced by clinicians. Both ctDNA and utDNA seem really promising in urothelial carcinoma diagnosis, staging and prognosis, response to therapy monitoring, detection of minimal residual disease and surveillance. The use of liquid biopsies in patients with urothelial carcinoma could further advance precision medicine in this population, facilitating personalized patient monitoring through non-invasive assays.",

author = "Rose, {Kyle M.} and Huelster, {Heather L.} and Meeks, {Joshua J.} and Faltas, {Bishoy M.} and Sonpavde, {Guru P.} and Lerner, {Seth P.} and Ross, {Jeffrey S.} and Spiess, {Philippe E.} and Grass, {G. Daniel} and Jain, {Rohit K.} and Kamat, {Ashish M.} and Aram Vosoughi and Liang Wang and Xuefeng Wang and Roger Li",

note = "Publisher Copyright: {\textcopyright} 2023, Springer Nature Limited.",

year = "2023",

month = jul,

doi = "10.1038/s41585-023-00725-2",

language = "English (US)",

volume = "20",

pages = "406--419",

journal = "Nature Reviews Urology",

issn = "1759-4812",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease

AU - Rose, Kyle M.

AU - Huelster, Heather L.

AU - Meeks, Joshua J.

AU - Faltas, Bishoy M.

AU - Sonpavde, Guru P.

AU - Lerner, Seth P.

AU - Ross, Jeffrey S.

AU - Spiess, Philippe E.

AU - Grass, G. Daniel

AU - Jain, Rohit K.

AU - Kamat, Ashish M.

AU - Vosoughi, Aram

AU - Wang, Liang

AU - Wang, Xuefeng

AU - Li, Roger

PY - 2023/7

Y1 - 2023/7

N2 - Precision medicine has transformed the way urothelial carcinoma is managed. However, current practices are limited by the availability of tissue samples for genomic profiling and the spatial and temporal molecular heterogeneity observed in many studies. Among rapidly advancing genomic sequencing technologies, non-invasive liquid biopsy has emerged as a promising diagnostic tool to reproduce tumour genomics, and has shown potential to be integrated in several aspects of clinical care. In urothelial carcinoma, liquid biopsies such as plasma circulating tumour DNA (ctDNA) and urinary tumour DNA (utDNA) have been investigated as a surrogates for tumour biopsies and might bridge many shortfalls currently faced by clinicians. Both ctDNA and utDNA seem really promising in urothelial carcinoma diagnosis, staging and prognosis, response to therapy monitoring, detection of minimal residual disease and surveillance. The use of liquid biopsies in patients with urothelial carcinoma could further advance precision medicine in this population, facilitating personalized patient monitoring through non-invasive assays.

AB - Precision medicine has transformed the way urothelial carcinoma is managed. However, current practices are limited by the availability of tissue samples for genomic profiling and the spatial and temporal molecular heterogeneity observed in many studies. Among rapidly advancing genomic sequencing technologies, non-invasive liquid biopsy has emerged as a promising diagnostic tool to reproduce tumour genomics, and has shown potential to be integrated in several aspects of clinical care. In urothelial carcinoma, liquid biopsies such as plasma circulating tumour DNA (ctDNA) and urinary tumour DNA (utDNA) have been investigated as a surrogates for tumour biopsies and might bridge many shortfalls currently faced by clinicians. Both ctDNA and utDNA seem really promising in urothelial carcinoma diagnosis, staging and prognosis, response to therapy monitoring, detection of minimal residual disease and surveillance. The use of liquid biopsies in patients with urothelial carcinoma could further advance precision medicine in this population, facilitating personalized patient monitoring through non-invasive assays.

UR - http://www.scopus.com/inward/record.url?scp=85151137449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151137449&partnerID=8YFLogxK

U2 - 10.1038/s41585-023-00725-2

DO - 10.1038/s41585-023-00725-2

M3 - Review article

C2 - 36977797

AN - SCOPUS:85151137449

SN - 1759-4812

VL - 20

SP - 406

EP - 419

JO - Nature Reviews Urology

JF - Nature Reviews Urology

IS - 7

ER -

Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this